Holen Sie sich die Stockscreener-App
0.808
0.37%
0.003
Handel nachbörslich:
.83
0.022
+2.72%
Schlusskurs vom Vortag:
$0.805
Offen:
$0.805
24-Stunden-Volumen:
428.85K
Relative Volume:
0.50
Marktkapitalisierung:
$85.69M
Einnahmen:
$15.33M
Nettoeinkommen (Verlust:
$-34.78M
KGV:
-1.977
EPS:
-0.4087
Netto-Cashflow:
$-28.66M
1W Leistung:
+2.28%
1M Leistung:
-1.98%
6M Leistung:
-25.19%
1J Leistung:
-44.28%
1-Tages-Spanne:
$0.8001
$0.8389
1-Wochen-Bereich:
$0.77
$0.88
52-Wochen-Spanne:
$0.7536
$2.22
Hyperfine Inc Stock (HYPR) Company Profile
Firmenname
Hyperfine Inc
Sektor
Branche
Telefon
866-796-6767
Adresse
351 NEW WHITFIELD STREET, GUILFORD
Compare HYPR vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HYPR
Hyperfine Inc
|
0.808 | 86.25M | 15.33M | -34.78M | -28.66M | -0.4087 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Hyperfine Inc Stock (HYPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2022-04-14 | Eingeleitet | Wells Fargo | Overweight |
Hyperfine Inc Aktie (HYPR) Neueste Nachrichten
Hyperfine stock reports 45 percent revenue growth - AD HOC NEWS
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026Slideshow (NASDAQ:HYPR) 2026-06-05 - Seeking Alpha
BTIG reiterates Hyperfine stock rating on commercial progress By Investing.com - Investing.com Nigeria
HYPR Reiterated by BTIG -- Price Target Maintained at $2.00 - GuruFocus
BTIG reiterates Hyperfine stock rating on commercial progress - Investing.com
BTIG reiterates Buy rating on Hyperfine, $2 price target - TradingView
Hyperfine Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Hyperfine stock holds steady as investors await fresh signals - AD HOC NEWS
Hyperfine completes enrolment in contrast-enhanced Swoop MRI Study - Indian Pharma Post
Hyperfine CEO Maria Sainz Wins 2026 MedtechWOMEN Leadership Award - citybiz
MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award - Business Wire
Hyperfine completes enrollment in contrast MRI study By Investing.com - Investing.com Australia
Hyperfine completes enrollment in contrast MRI study - Investing.com
Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents - Business Wire
Hyperfine stock maintains buy rating at BTIG on AI software update - Investing.com Canada
Lioness Medtech Showcasing Hyperfine Swoop at Röntgenveckan 2026 - marketscreener.com
HYPR Q2 2026 Earnings: EPS Loss of -$0.09 Narrowly Beats Estimates, Stock Slips 1.4%Profit Recovery Report - dars.gov.et
HYPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hyperfine (HYPR) Holds at $0.81, Pressing Against Support After Mild PullbackMarket Neutral Pair - siam.in
Hyperfine Forms Global Neurosurgery Advisory Council - Medical Product Outsourcing
Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference - Yahoo Finance
Hyperfine reports 3,000 scans completed in first office year By Investing.com - Investing.com Nigeria
Hyperfine reports 3,000 scans completed in first office year - Investing.com
Hyperfine (HYPR) Earnings Update: The Available Earnings Metric Delivers a Beat at the Close; Market Response: Shares Finish 4.21% Down for the Current SessionEnergy Earnings Report - vinanet.vn
HYPR | Hyperfine, Inc. Class A FinancialsRevenue Breakdown - Quiver Quantitative
Hyperfine (HYPR) Q2 2026 Earnings Call Transcript - AOL.com
BTIG reiterates Hyperfine stock rating on FDA software clearance By Investing.com - Investing.com Canada
BTIG reiterates Hyperfine stock rating on FDA software clearance - Investing.com
Hyperfine Wins FDA Clearance for Next Optive AI Software - Medical Product Outsourcing
Hyperfine receives FDA clearance for Swoop MRI software update - Investing.com
Hyperfine receives FDA clearance for Swoop MRI software update By Investing.com - Investing.com South Africa
Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings - Business Wire
Hyperfine, Inc. (NASDAQ:HYPR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Hyperfine Inc. (HYPR) Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Edge LowerEarnings Momentum Score - vinanet.vn
HYPR Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares SlipEarnings Stability Report - vinanet.vn
Hyperfine Inc. (HYPR) Edges Lower to $0.9 as Shares Trade Within Narrow RangeLiquidity Order Flow - vinanet.vn
Hyperfine, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HYPR) 2026-08-10 - Seeking Alpha
HYPR Reiterates by B. Riley Securities -- Price Target Lowers to $1.60 - GuruFocus
B. Riley Financial Reaffirms Buy Rating for Hyperfine (NASDAQ:HYPR) - MarketBeat
HYPR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.83%EPS Surprise History - dars.gov.et
Hyperfine Q2 2026 slides: 45% revenue growth, AI-powered MRI expansion - Investing.com Australia
Hyperfine Inc (HYPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Hyperfine Touts Positive Results From Portable MRI Study - Medical Product Outsourcing
Hyperfine, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Hyperfine (NASDAQ:HYPR) Announces Quarterly Earnings Results - MarketBeat
Hyperfine Q2 Earnings Call Highlights - MarketBeat
Finanzdaten der Hyperfine Inc-Aktie (HYPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hyperfine Inc-Aktie (HYPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HALE BRETT | CFO and CAO |
Aug 24 '26 |
Sale |
0.85 |
7,345 |
6,273 |
592,420 |
| HALE BRETT | CFO and CAO |
May 26 '26 |
Sale |
1.65 |
6,047 |
9,978 |
599,765 |
| TEISSEYRE THOMAS | Chief Operating Officer |
May 26 '26 |
Sale |
1.65 |
6,047 |
9,978 |
678,601 |
| TEISSEYRE THOMAS | Chief Operating Officer |
Mar 23 '26 |
Sale |
1.21 |
24,188 |
29,267 |
354,648 |
| HALE BRETT | CFO and CAO |
Mar 23 '26 |
Sale |
1.21 |
24,188 |
29,267 |
275,812 |
| TEISSEYRE THOMAS | Chief Operating Officer |
Feb 13 '26 |
Sale |
1.11 |
821 |
913 |
378,836 |
| TEISSEYRE THOMAS | Chief Operating Officer |
Nov 19 '25 |
Sale |
1.08 |
1,405 |
1,517 |
379,657 |
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):